PLoS ONE (Jan 2022)

Dysregulation of the leukocyte signaling landscape during acute COVID-19

  • Isaiah R. Turnbull,
  • Anja Fuchs,
  • Kenneth E. Remy,
  • Michael P. Kelly,
  • Elfaridah P. Frazier,
  • Sarbani Ghosh,
  • Shin-Wen Chang,
  • Monty B. Mazer,
  • Annie Hess,
  • Jennifer M. Leonard,
  • Mark H. Hoofnagle,
  • Marco Colonna,
  • Richard S. Hotchkiss

Journal volume & issue
Vol. 17, no. 4

Abstract

Read online

The global COVID-19 pandemic has claimed the lives of more than 750,000 US citizens. Dysregulation of the immune system underlies the pathogenesis of COVID-19, with inflammation mediated tissue injury to the lung in the setting of suppressed systemic immune function. To define the molecular mechanisms of immune dysfunction in COVID-19 we utilized a systems immunology approach centered on the circulating leukocyte phosphoproteome measured by mass cytometry. We find that although COVID-19 is associated with wholesale activation of a broad set of signaling pathways across myeloid and lymphoid cell populations, STAT3 phosphorylation predominated in both monocytes and T cells. STAT3 phosphorylation was tightly correlated with circulating IL-6 levels and high levels of phospho-STAT3 was associated with decreased markers of myeloid cell maturation/activation and decreased ex-vivo T cell IFN-γ production, demonstrating that during COVID-19 dysregulated cellular activation is associated with suppression of immune effector cell function. Collectively, these data reconcile the systemic inflammatory response and functional immunosuppression induced by COVID-19 and suggest STAT3 signaling may be the central pathophysiologic mechanism driving immune dysfunction in COVID-19.